Blood test for colon cancer screening beneficial for some seniors, but not for many others
A new study of U.S. veterans ages 70 and older finds that the healthiest get the most benefit from current colon cancer screening methods. However, for many less healthy veterans the burdens of screening may outweigh the benefits.
"This study shows that we really need to target screening in older adults, so that those who will benefit do get screened and followed-up while those who won't benefit aren't exposed to unnecessary burdens," said Christine E. Kistler, MD, assistant professor of Family Medicine at the University of North Carolina at Chapel Hill and lead author of the study.
The study was published online on May 9, 2011, by the journal Archives of Internal Medicine. Kistler led the study while completing a geriatrics fellowship at the University of California, San Francisco and the San Francisco Veterans Affairs Medical Center. She has since joined the faculty at the UNC School of Medicine.
In the study, 212 patients ages 70 and older who were treated at four Veterans Affairs medical facilities were followed for 7 years after receiving a positive result in a fecal occult blood test (FOBT). The test, which determines whether or not occult (hidden) blood is present in the stool, is the most common method used in the VA health system as an initial screen for colon cancer. A follow-up colonoscopy within one year is recommended for patients with a positive FOBT.
The study found that a little more than half of the patients received a follow-up colonoscopy. Among those who did, more than 25 percent were found to have significant disease such as precancerous adenomas or cancer, were treated, and survived for more than five years. However, 59 percent of those who received follow-up colonoscopy did not have cancer, 16 percent died of other causes within 5 years, and 10 percent suffered complications from either colonoscopy or cancer treatment.
Among those who did not receive follow-up colonoscopy, nearly half died of other causes within five years of their positive FOBT. Four patients ultimately died of colon cancer -- three within the first 5 years of their positive FOBT.
Of the 212 patients in the study, the researchers defined 33 patients, a little more than 15 percent, as receiving a net benefit from their positive FOBT. Another 30 patients, about 14 percent, were defined as receiving indeterminate benefit. The remaining 149 patients, about 70 percent, were defined as receiving a net burden from colorectal cancer screening.
Kistler said there was "a spectrum of burden" among those in the net burden group. For some the burden was that they never received a follow-up colonoscopy. Others received a colonoscopy but it found no evidence of cancer, and some died of causes other than colon cancer. In each of these examples, the patients received no benefit as a result of their positive FOBT, Kistler said.
"This study shows that we need to do a better job of targeting colon cancer screening to those seniors who are healthy and functional and are likely to benefit. At the same time, this study also shows that we need to seriously examine why those seniors who are not likely to benefit are being subjected to colon cancer screening," Kistler said.
Provided by University of North Carolina School of Medicine
- Investment in CRC screening targeting pre-medicare population could cut medicare treatment costs Oct 18, 2010 | not rated yet | 0
- Black Americans are at higher risk for colon polyps Sep 24, 2008 | not rated yet | 0
- Mail and electronic reminders may increase colon cancer screening Feb 23, 2009 | not rated yet | 0
- Colorectal cancer screening remains essential for elderly Americans Oct 15, 2007 | not rated yet | 0
- Cost-savings of colorectal cancer screening as treatment costs increase Sep 24, 2009 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
How can there be villous adenoma in colon, if there are no villi there
12 hours ago As title suggest. Thanks :smile:
How can there be a term called "intestinal metaplasia" of stomach
May 21, 2013 Hello everyone, Ok Stomach's normal epithelium is simple columnar, now in intestinal type of adenocarcinoma of stomach it undergoes "intestinal...
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013 From pressure-volume curve of the lung and chest wall (attached photo), I don't understand why would the elastic recoil pressure of the lung is...
If you became brain-dead, would you want them to pull the plug?
May 17, 2013 I'd want the rest of me to stay alive. Sure it's a lousy way to live but it beats being all-the-way dead. Maybe if I make it 20 years they'll...
MRI bill question
May 15, 2013 Dear PFers, The hospital gave us a $12k bill for one MRI (head with contrast). The people I talked to at the hospital tell me that they do not...
Ratio of Hydrogen of Oxygen in Dessicated Animal Protein
May 13, 2013 As an experiment, for the past few months I've been consuming at least one portion of Jell-O or unflavored Knox gelatin per day. I'm 64, in very...
- More from Physics Forums - Medical Sciences
More news stories
(HealthDay)—The American Cancer Society, which is celebrating on Wednesday a century of fighting a disease once viewed as a death sentence, is making a pledge to put itself out of business.
Cancer 2 hours ago | not rated yet | 0
National Lung Screening Trial (NLST) investigators also conclude that the 20 percent reduction in lung cancer mortality with low-dose computed tomography (LDCT) versus chest X-ray (CXR) screening previously reported in the ...
Cancer 2 hours ago | not rated yet | 0
Researchers have developed a new drug delivery system that allows inhalation of chemotherapeutic drugs to help treat lung cancer, and in laboratory and animal tests it appears to reduce the systemic damage ...
Cancer 5 hours ago | not rated yet | 0 |
When turned on, the gene p53 turns off cancer. However, when existing drugs boost p53, only a few tumors die – the rest resist the challenge. A study published in the journal Cell Reports shows how: tumors that live even i ...
Cancer 6 hours ago | not rated yet | 0 |
Study leader, Professor John Mathews from the University of Melbourne said this small increase in cancer risk must be weighed against the undoubted benefits from CT scans in diagnosing and monitoring disease.
Cancer 10 hours ago | not rated yet | 0
Calorie information in fast food restaurants used by 40 percent of 9-18 year olds when making food choices
A new study published online today (Thursday) in the Journal of Public Health has found that of young people who visited fast food or chain restaurants in the U.S. in 2010, girls and youth who were obese were more likely ...
33 minutes ago | not rated yet | 0
(HealthDay)—Migraines and depression can each cause a great deal of suffering, but new research indicates the combination of the two may be linked to something else entirely—a smaller brain.
3 hours ago | 5 / 5 (1) | 0 |
Swiss scientists reveal the mechanism responsible for aging hidden deep within mitochondria—and dramatically slow it down in worms by administering antibiotics to the young.
6 hours ago | 4.5 / 5 (2) | 0 |
Until now, little was scientifically known about the human potential to cultivate compassion—the emotional state of caring for people who are suffering in a way that motivates altruistic behavior.
3 hours ago | not rated yet | 2 |
Researchers from Queen Mary, University of London have led the largest sequencing study of human disease to date, investigating the genetic basis of six autoimmune diseases.
6 hours ago | not rated yet | 0 |
An independent panel of experts on Wednesday recommended US approval of a new Merck sleeping pill called suvorexant, but expressed concerns over the highest dosage and risks of drowsy daytime driving.
1 hour ago | not rated yet | 0